

# Thermal characterization and compatibility studies of norfloxacin for development of extended release tablets

P. R. Oliveira · L. S. Bernardi · F. S. Murakami ·  
C. Mendes · M. A. S. Silva

ICTAC2008 Conference  
© Akadémiai Kiadó, Budapest, Hungary 2009

**Abstract** Norfloxacin (NFX) is a synthetic antibacterial drug. The development of extended release tablets improves the patients' comfort and compliance, resulting in lower discontinuation of the therapy; with consequently decrease in bacterial resistance. In the present work, the thermal behavior of NFX was investigated using TG and DSC techniques. Isothermal and non-isothermal methods were employed to determine kinetic data of decomposition process. Compatibility studies between NFX and pharmaceutical excipients, including three hydrophilic polymers were carried out in order to develop a new formulation of NFX to obtain extended release tablets with an approved quality.

**Keywords** Norfloxacin · Thermal characterization · Kinetic studies · Compatibility studies

## Introduction

Norfloxacin, chemically known as 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1-ethyl-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid (Fig. 1a) [1]. It is currently used as a broad spectrum antibacterial drug, being the firstly selected drug for the treatment of diseases caused by *Campylobacter*, *E. coli*, *Salmonella*, *Shigella* and *V. cholera* [2, 3]. The drug is also used for the treatment of gonorrhoea as well as infection of eyes and


urinary tract [2]. Resistance in Gram-negative bacteria has become common, making the therapeutic decisions more difficult. Increasing bacterial resistance to currently available quinolones has reduced their effectiveness and may compromise future use of this class of drugs [4, 5].

The development of controlled-release formulations is a successful area in the pharmaceutical industry because expenses of new drug development are very high, and novel innovation is at an all-time low. Hydrophilic matrices are one of the most used controlled delivery systems in the world, due to the simple technology and low cost. Among the various hydrophilic polymers employed, hydroxypropyl methylcellulose (HPMC, Fig. 1b) is the most commonly used, due to its versatility, compatibility with many drugs and safety [6]. Nevertheless, high molecular mass polyethylene oxides (PEOs, Fig. 1c) have been proposed as an alternative to HPMC [7].

Thermoanalytical techniques measure changes in physical and/or chemical properties of the sample as a function of temperature. There are many possible applications in pharmaceutical industry, for example, identification, characterization of active and inactive ingredients, routine analysis, quality control and stability study [8, 9]. Kinetic parameters (activation energy, frequency factor and reaction order) can be measured by thermoanalytical methods according to progress of reactions [10–12]. The successful formulation of a stable and effective solid dosage form depends on the careful selection of the excipients [8, 13] and on the characterization of solid-state properties using appropriate analytical methodologies [14–16]. The compatibility studies using thermal analysis present advantageous to readily available knowledge of any physical and chemical interactions between drugs and excipients which might give rise to changes in chemical nature, stability, solubility, absorption and therapeutic response of drugs

---

P. R. Oliveira (✉) · L. S. Bernardi · F. S. Murakami ·  
C. Mendes · M. A. S. Silva  
Department of Pharmaceutical Sciences, Health Science Centre,  
Federal University of Santa Catarina, Florianópolis,  
SC 88040-900, Brazil  
e-mail: prenataloliveira@gmail.com



**Fig. 1** Chemical structure of NFX (a), HPMC (b) and PEOs (c)

[12]. In particular differential scanning calorimetry (DSC) has been proposed as a rapid method for evaluating physicochemical interactions between components of the formulation through comparison of thermal curves of pure substances with curve obtained from a 1:1 mixture, and therefore selecting excipients with suitable compatibility [10, 15, 17–21].

The aim of this study was to perform the physicochemical solid-state characterization of norfloxacin and different polymers, to analyze the kinetic parameters under isothermal and non-isothermal conditions, and to carry out compatibility studies, to begin the development of a new formulation of NFX extended release tablets.

## Experimental

### Materials

Norfloxacin (NFX) bulk material was kindly donated by União Química Farmacêutica Nacional (Embu-Guaçu, SP, Brazil). The polymers tested were: Polyox WSR N80 NF, Polyox WSR 301 NF, and Methocel K100 Premium LV CR (all from Colorcon do Brasil, São Paulo, Brazil). The pharmaceutical excipients tested were microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, lactose monohydrated and Opadry II White.

### Methods

#### *Differential scanning calorimetry and thermogravimetric analysis*

The DSC curves were obtained on Shimadzu DSC-60 cell (Kyoto, Japan) using aluminum crucibles with about 1.5 mg of samples. The temperature range was from 30 to 500 °C at a heating rate of 10 °C min<sup>-1</sup> in dynamic N<sub>2</sub> atmosphere

with the flow rate of 50 mL min<sup>-1</sup>. The DSC equipment was preliminarily calibrated with standard reference of indium (m.p. 156.6 °C;  $\Delta H_{\text{fus}} = -28.54 \text{ J g}^{-1}$ ) and zinc (m.p. 419.5 °C). The compatibility studies were performed with binary mixtures of NFX and each excipient (1:1; *m/m*). Thermogravimetric (TG) experiments were measured on Shimadzu thermobalance model TGA-50 (Kyoto, Japan) in the temperature range of 30–800 °C, using platinum crucibles with approximately 4 mg of samples, under dynamic N<sub>2</sub> atmosphere (50 mL min<sup>-1</sup>) at a heating rate of 10 °C min<sup>-1</sup>. The equipment was preliminarily calibrated with standard reference of calcium oxalate. Non-isothermal kinetic investigation of NFX was performed from TG data by application of Ozawa's method [22]. The graph of mass loss versus temperature of five TG curves was obtained at different heating rates (2.5, 5.0, 10, 15, and 20 °C min<sup>-1</sup>), under N<sub>2</sub> atmosphere. For isothermal method, the temperature was from 230 to 270 °C, with 10 °C temperature increment, in N<sub>2</sub> atmosphere. A graphic of  $\ln t$  versus  $1/T$  (K<sup>-1</sup>) was plotted and linear regression was applied.

#### *X-ray powder diffraction*

For characterization of crystallinity, X-ray diffraction patterns were obtained on a Siemens diffractometer model D 5000, with tube of CuK $\alpha$ , voltage of 40 kV and current of 40 mA, in the range of 3–40 ( $2\theta$ ) with a pass time of 1 s.

#### *Diffuse reflectance infrared fourier transform spectroscopy*


The diffuse reflectance infrared Fourier transform spectroscopy (DRIFT) spectra were measured in a Shimadzu spectrophotometer (Prestige), in a scan range of 400–4,000 cm<sup>-1</sup> with an average of over 32 scans at a spectral resolution of 4 cm<sup>-1</sup> in KBr. A background spectrum was obtained for each experimental condition.

#### *Scanning electron microscopy*

The photomicrographs of NFX and the polymers were observed by using a Phillips scanning electron microscope (SEM), model XL30. Samples were mounted onto metal stubs using double-side adhesive tape, vacuum-coated with gold (350 Å) in a Polaron E 5000 and directly analyzed under SEM ( $N = 50, 200, \text{ and } 1,000$ ).

## Results and discussion

DSC curve of norfloxacin (Fig. 2a) showed a sharp endothermic event ( $T_{\text{peak}}$ ) at 219.4 °C ( $\Delta H_{\text{fusion}} = -101.51 \text{ J g}^{-1}$ ) corresponding to melting point followed by an exothermal




**Fig. 2** DSC and TG/DTG curves of norfloxacin (a), Polyox WSR 301 (b), Polyox WSR N80 (c), and Methocel K100 LV CR (d) in dynamic nitrogen atmosphere ( $50 \text{ mL min}^{-1}$ ) and heating rate of  $10 \text{ }^\circ\text{C min}^{-1}$


event. The decomposition was defined in two major endothermic stages. This was confirmed by TG/DTG curves that indicated thermal decomposition in the following temperature range:  $330\text{--}376 \text{ }^\circ\text{C}$  ( $\Delta m = 47.4\%$ ) and  $421\text{--}455 \text{ }^\circ\text{C}$  ( $\Delta m = 27.8\%$ ). The DSC curve of Polyox WSR 301 (Fig. 2b) and Polyox WSR N80 (Fig. 2c) showed sharp endothermic peaks at  $69.3 \text{ }^\circ\text{C}$  ( $\Delta H_{\text{fusion}} = -162.70 \text{ J g}^{-1}$ ) and  $65.3 \text{ }^\circ\text{C}$  ( $\Delta H_{\text{fusion}} = -180.36 \text{ J g}^{-1}$ ), respectively, corresponding to melting event. The TG/DTG curves indicated one thermal decomposition step in the temperature range of  $397\text{--}433 \text{ }^\circ\text{C}$  ( $\Delta m = 95.9\%$ ) for Polyox WSR 301 and  $394\text{--}432 \text{ }^\circ\text{C}$  ( $\Delta m = 95.8\%$ ) for Polyox WSR N80. The similarity of these thermal decomposition profiles can be explained by the same polymer chemical structure; the only difference is the molecular mass, 4,000,000 Da (Polyox WSR 301) and 200,000 Da (Polyox WSR N80). Different molecular masses usually are tested in the development of extended release tablets because its increase leads to an increase in gel strength, which tends to decrease the diffusion of the drug from the matrix. DSC curve of Methocel K100 LV (Fig. 2d) showed a broad endothermic event between  $93\text{--}140 \text{ }^\circ\text{C}$  ( $\Delta H = -120.97 \text{ J g}^{-1}$ ) and TG/DTG curves indicated thermal decomposition in the temperature range of  $360\text{--}394 \text{ }^\circ\text{C}$  ( $\Delta m = 83.6\%$ ).

Based on the photomicrographs obtained from scanning electron microscopy, orthorhombic crystals were observed for NFX (Fig. 3a). A particle size variation can be visualized for both Polyox samples (Fig. 3b, c). An amorphous characteristic was observed for Methocel K100 (Fig. 3d).

X-ray powder diffraction (XRPD) studies were performed in order to obtain more information about the crystalline characteristics. The  $2\theta$  values of the diffraction peaks (Fig. 4) for NFX were  $2\theta = 7.87, 9.93, 10.63, 11.98,$




**Fig. 3** SEM of NFX (a), Polyox WSR 301 (b), Polyox WSR N80 (c), and Methocel K100 LC CR (d). The photomicrograph (a) was taken at a magnification of  $50\times$ , and (b–d) of  $100\times$




**Fig. 4** X-ray diffraction spectra of NFX (a), Polyox WSR 301 (b), Polyox WSR N80 (c), and Methocel K100 LC CR (d)

$13.38, 14.98, 16.08, 18.88, 20.78,$  and  $25.08$ . For both Polyox polymers, only two intensive peaks were observed:  $2\theta = 19.13$  and  $23.33$ . For Methocel K100, only two broad peaks, with low intensity, between  $2\theta = 5.7\text{--}13.3$  and  $15.53\text{--}25.5$ , were observed, indicating an amorphous state for this polymer.

The IR spectra of quinolones are more representative in the region  $1,800\text{--}1,300 \text{ cm}^{-1}$  [23]. The IR spectrum (Fig. 5) of NFX exhibits a stretching vibration band at about  $1,716 \text{ cm}^{-1}$  ( $-\text{COOH}$  stretching) and  $1,631 \text{ cm}^{-1}$  (pyridone keto). For Polyox WSR 301 and N80, it was observed bands in  $2,915$  and  $1,465 \text{ cm}^{-1}$  (stretching  $-\text{CH}_2-$ ) and intense bands in  $1,150\text{--}1,085 \text{ cm}^{-1}$ , which is attributed to asymmetric axial deformation C–O–C, characteristic of aliphatic ethers, confirming the identification of the polymers. Methocel K100 IR spectra showed absorption bands at  $3,440 \text{ cm}^{-1}$  (O–H stretching),  $2,904 \text{ cm}^{-1}$  (C–H stretching),  $1,643 \text{ cm}^{-1}$  (C=O), and  $1,066 \text{ cm}^{-1}$  (C–O–C).




**Fig. 5** DRIFT spectra of Norfloxacin (A), Polyox WSR 301 (B), Polyox WSR N80 (C), and Methocel K100 LC CR (D)



**Fig. 6** **a** TG curves obtained for the non-isothermic study of NFX at 2.5, 5, 10, 15, and 20 °C min<sup>-1</sup>. **b** Isothermal TG curves of NFX obtained between 230 and 270 °C, with a temperature increment of 10 °C

For non-isothermic study, the superposition of the TG curves of NFX is shown in Fig. 6a. Ozawa's method was applied in order to determine the activation energy ( $E_a$ ), Arrhenius frequency factor ( $A$ ) and order of reaction at the beginning of first thermal decomposition step at around 300–350 °C. The  $E_a$ , calculated was 126 kJ mol<sup>-1</sup>, the Arrhenius frequency factor was  $4.029 \times 10^9$  min<sup>-1</sup> and order of reaction followed a zero order reaction ( $n = 0$ ).

The isothermal TG curves of NFX are illustrated in Fig. 6b. These curves were used to obtain a graphic of  $\ln t$  versus the reciprocal of temperature  $1/T$  (K<sup>-1</sup>). From this linear regression method, the equation obtained was  $y = -16.098x + 26.382$  ( $R = 0.9982$ ). The activation energy calculated from the product of 16.098 with the molar gas constant ( $R = 8.314$ ) and was  $E_a = 134$  kJ mol<sup>-1</sup>. This result is in agreement with the value obtained from the dynamic method. The selection of adequate excipients for a new formulation is based on the characteristics of the drug and its compatibility with other components. Moreover, excipients can influence the dissolution profile affecting the bioavailability of the drug. The results from the compatibility studies between NFX and excipients are shown in



**Fig. 7** DSC curves of NFX and excipients obtained in dynamic nitrogen atmosphere (50 mL min<sup>-1</sup>) and heating of rate 10 °C min<sup>-1</sup>

Fig. 7, where the DSC curves can be considered as superposition of the curves of pure compounds indicating that there is no interaction, and therefore no physical-chemical incompatibility.

## Conclusions

The thermal behaviour and the solid-state characterization of NFX and the polymers were carried out by means of TG, DSC, DRIFT, SEM, and XRPD. The obtained isothermal and non-isothermal kinetic parameters can be used as reference values for the routine quality control of NFX. The results demonstrated the applicability of DSC as a fast screening tool for selection of adequate excipients at the early stages of pre-formulation studies. No interaction was observed for NFX and the tested excipients, making feasible the development of a high quality formulation of NFX extended release tablets.

**Acknowledgements** The authors wish to thank CNPq and CAPES for the support.

## References

- Andersson MI, MacGowan AP. Development of the quinolones. *J Antimicrob Chemother.* 2003;51(Suppl S1):1–11.
- Emmerson AM, Jones AM. The quinolones: decades of development and use. *J Antimicrob Chemother.* 2003;51:13–20.
- Van Bambeke F, Michot J-M, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. *Clin Microbiol Infect.* 2005;11:256–80.
- Sheng W-H, Chen Y-C, Wang J-T, Chang S-C, Luh K-T, Hsieh W-C. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. *Diagn Microbiol Infect Dis.* 2002;43:141–7.
- Alexiou Z, Mouktaroudi M, Koratzanis G, Papadopoulos A, Kavatha D, Kanellakopoulou K, et al. The significance of

- compliance for the success of antimicrobial prophylaxis in recurrent lower urinary tract infections: the Greek experience. *Int J Antimicrob Agents*. 2007;30:40–3.
6. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). *Adv Drug Deliv Rev*. 2001;48:139–57.
  7. Maggi L, Bruni R, Conte U. High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms. *Int J Pharm*. 2000;195:229–38.
  8. Gombás A, Szabó-Révész P, Kata M, Regdon G, Erős I. Quantitative determination of crystallinity of  $\alpha$ -lactose monohydrate by DSC. *J Therm Anal Calorim*. 2002;68:503–10.
  9. Giron D. Applications of thermal analysis and coupled techniques in pharmaceutical industry. *J Therm Anal Calorim*. 2002;68:335–57.
  10. Cides LCS, Araújo AAS, Santos-Filho M, Matos JR. Thermal behaviour, compatibility study and decomposition kinetics of glimepiride under isothermal and non-isothermal conditions. *J Therm Anal Calorim*. 2006;84:441–5.
  11. Tița B, Marian E, Tița D, Vlase G, Doca N, Vlase T. Comparative kinetic study of decomposition of some diazepam derivatives under isothermal and non-isothermal conditions. *J Therm Anal Calorim*. 2008;94:447–52.
  12. Felix FS, Cides da Silva LC, Angnes L, Matos JR. Thermal behavior study and decomposition kinetics of salbutamol under isothermal and non-isothermal conditions. *J Therm Anal Calorim*. 2009;95:877–80.
  13. Medeiros ACD, Correia LP, Simões MOS, Macêdo RO. Technological quality determination of pharmaceutical disintegrant by DSC cooling and DSC photovisual. *J Therm Anal Calorim*. 2007;88:311–5.
  14. Gandhi R, Pillai O, Thilagavathi R, Gopalakrishnan B, Kaul CL, Panchagnula R. Characterization of azithromycin hydrates. *Eur J Pharm Sci*. 2002;16:175–84.
  15. Abbas D, Kaloustian J, Orneto C, Piccerelle P, Portugal H, Nicolay A. DSC and physico-chemical properties of a substituted pyridoquinoline and its interaction study with excipients. *J Therm Anal Calorim*. 2008;93:353–60.
  16. Ramos LA, Cavalheiro ÉTG. Thermal behavior of loratadine. *J Therm Anal Calorim*. 2007;87:831–4.
  17. Araújo AAS, Storpirtis S, Mercuri LP, Carvalho FMS, Santos-Filho M, Matos JR. Thermal analysis of the antiretroviral zidovudine (AZT) and evaluation of the compatibility with excipients used in solid dosage forms. *Int J Pharm*. 2003;260:303–14.
  18. Mura P, Gratteri P, Faucci MT. Compatibility studies of multi-component tablet formulations, DSC and experimental mixture design. *J Therm Anal Calorim*. 2002;68:541–51.
  19. Mora PC, Cirri M, Mura P. Differential scanning calorimetry as a screening technique in compatibility studies of DHEA extended release formulations. *J Pharm Biomed Anal*. 2006;42:3–10.
  20. Santos AFO, Basílio ID Jr, de Souza FS, Medeiros AFD, Pinto MF, de Santana DP, et al. Application of thermal analysis in study of binary mixtures with metformin. *J Therm Anal Calorim*. 2008;93:361–4.
  21. Misra M, Misra AK, Panpalia GM. Interaction study between pefloxacin mesilate and some diluents using DSC supported with isothermal method. *J Therm Anal Calorim*. 2007;89:803–8.
  22. Ozawa T. Thermal analysis—review and prospect. *Thermochim Acta*. 2000;355:35–42.
  23. Shaikh AR, Giridhar R, Yadav MR. Bismuth-norfloxacin complex: synthesis, physicochemical and antimicrobial evaluation. *Int J Pharm*. 2007;332:24–30.